{
  "docId": "019de071-1981-7442-94ed-ee285d10f59b",
  "docSlug": "c18efbd116f640ca1060cd96d0c18250",
  "documentTitle": "Alkermes | Results Presentation Deck | 31 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 31,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_messages",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a human body diagram to map clinical response areas.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1981-7442-94ed-ee285d10f59b/5",
  "deckHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b",
  "deckJsonHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b.json",
  "deckAnchorHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.53,
        "y": 0.25
      },
      "kind": "image",
      "text": "Human body diagram showing target organs for monotherapy and combination responses.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1229f618-784c-46b4-984e-f4898cff5a3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Design derives from natural biology; Inherently active, stable fusion protein; Demonstrated durable and deepening responses; Differentiated and rapidly advancing clinical development program.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b949b0f-91f9-4e0f-8dfb-ade7d17e8cec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.55,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Monotherapy and Combination Responses*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a41dd4d9-631b-48d4-bbe2-b1f7b7557dd6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "* Includes one response from ARTISTRY-2, which has recently opened expansion cohorts for enrollment at the recommended phase 2 dose. NSCLC: Non-Small Cell Lung Cancer; SCLC: Small Cell Lung Cancer; RCC: Renal cell carcinoma; GEJ: Esophagogastric junction",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4947e4e2-8bda-4037-a7aa-0856d0d262ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Nemvaleukin Alfa: Unique Cytokine Designed to Harness Validated IL-2 Pathway Biology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a31821ae-feb1-46cd-95f2-b55209a9997d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "9d10978f-3990-4d84-8bb4-62cb736a5066",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The presentation highlights the need for new treatments for certain types of cancer",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 8,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "38371bff-6368-45c8-9640-033e6721da71",
      "evidence": "The presentation highlights the need for new treatments",
      "position": 1,
      "objective": "What are the consequences of not having effective treatments for certain types of cancer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}